Co-Infection with Onchocerca Volvulus and Loa Loa Microfilariae in Central Cameroon: Are These Two Species Interacting?
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Functional Parasitic Worm Secretome: Mapping the Place of Onchocerca Volvulus Excretory Secretory Products
pathogens Review The Functional Parasitic Worm Secretome: Mapping the Place of Onchocerca volvulus Excretory Secretory Products Luc Vanhamme 1,*, Jacob Souopgui 1 , Stephen Ghogomu 2 and Ferdinand Ngale Njume 1,2 1 Department of Molecular Biology, Institute of Biology and Molecular Medicine, IBMM, Université Libre de Bruxelles, Rue des Professeurs Jeener et Brachet 12, 6041 Gosselies, Belgium; [email protected] (J.S.); [email protected] (F.N.N.) 2 Molecular and Cell Biology Laboratory, Biotechnology Unit, University of Buea, Buea P.O Box 63, Cameroon; [email protected] * Correspondence: [email protected] Received: 28 October 2020; Accepted: 18 November 2020; Published: 23 November 2020 Abstract: Nematodes constitute a very successful phylum, especially in terms of parasitism. Inside their mammalian hosts, parasitic nematodes mainly dwell in the digestive tract (geohelminths) or in the vascular system (filariae). One of their main characteristics is their long sojourn inside the body where they are accessible to the immune system. Several strategies are used by parasites in order to counteract the immune attacks. One of them is the expression of molecules interfering with the function of the immune system. Excretory-secretory products (ESPs) pertain to this category. This is, however, not their only biological function, as they seem also involved in other mechanisms such as pathogenicity or parasitic cycle (molting, for example). Wewill mainly focus on filariae ESPs with an emphasis on data available regarding Onchocerca volvulus, but we will also refer to a few relevant/illustrative examples related to other worm categories when necessary (geohelminth nematodes, trematodes or cestodes). -
Pathophysiology and Gastrointestinal Impacts of Parasitic Helminths in Human Being
Research and Reviews on Healthcare: Open Access Journal DOI: 10.32474/RRHOAJ.2020.06.000226 ISSN: 2637-6679 Research Article Pathophysiology and Gastrointestinal Impacts of Parasitic Helminths in Human Being Firew Admasu Hailu1*, Geremew Tafesse1 and Tsion Admasu Hailu2 1Dilla University, College of Natural and Computational Sciences, Department of Biology, Dilla, Ethiopia 2Addis Ababa Medical and Business College, Addis Ababa, Ethiopia *Corresponding author: Firew Admasu Hailu, Dilla University, College of Natural and Computational Sciences, Department of Biology, Dilla, Ethiopia Received: November 05, 2020 Published: November 20, 2020 Abstract Introduction: This study mainly focus on the major pathologic manifestations of human gastrointestinal impacts of parasitic worms. Background: Helminthes and protozoan are human parasites that can infect gastrointestinal tract of humans beings and reside in intestinal wall. Protozoans are one celled microscopic, able to multiply in humans, contributes to their survival, permits serious infections, use one of the four main modes of transmission (direct, fecal-oral, vector-borne, and predator-prey) and also helminthes are necked multicellular organisms, referred as intestinal worms even though not all helminthes reside in intestines. However, in their adult form, helminthes cannot multiply in humans and able to survive in mammalian host for many years due to their ability to manipulate immune response. Objectives: The objectives of this study is to assess the main pathophysiology and gastrointestinal impacts of parasitic worms in human being. Methods: Both primary and secondary data were collected using direct observation, books and articles, and also analyzed quantitativelyResults and and conclusion: qualitatively Parasites following are standard organisms scientific living temporarily methods. in or on other organisms called host like human and other animals. -
Performance of Two Serodiagnostic Tests for Loiasis in A
Performance of two serodiagnostic tests for loiasis in a Non-Endemic area Federico Gobbi, Dora Buonfrate, Michel Boussinesq, Cédric Chesnais, Sébastien Pion, Ronaldo Silva, Lucia Moro, Paola Rodari, Francesca Tamarozzi, Marco Biamonte, et al. To cite this version: Federico Gobbi, Dora Buonfrate, Michel Boussinesq, Cédric Chesnais, Sébastien Pion, et al.. Perfor- mance of two serodiagnostic tests for loiasis in a Non-Endemic area. PLoS Neglected Tropical Dis- eases, Public Library of Science, 2020, 14 (5), pp.e0008187. 10.1371/journal.pntd.0008187. inserm- 02911633 HAL Id: inserm-02911633 https://www.hal.inserm.fr/inserm-02911633 Submitted on 4 Aug 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. PLOS NEGLECTED TROPICAL DISEASES RESEARCH ARTICLE Performance of two serodiagnostic tests for loiasis in a Non-Endemic area 1 1 2 2 Federico GobbiID *, Dora Buonfrate , Michel Boussinesq , Cedric B. Chesnais , 2 1 1 1 3 Sebastien D. Pion , Ronaldo Silva , Lucia Moro , Paola RodariID , Francesca Tamarozzi , Marco Biamonte4, Zeno Bisoffi1,5 1 IRCCS Sacro -
Hookworm-Related Cutaneous Larva Migrans
326 Hookworm-Related Cutaneous Larva Migrans Patrick Hochedez , MD , and Eric Caumes , MD Département des Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, Paris, France DOI: 10.1111/j.1708-8305.2007.00148.x Downloaded from https://academic.oup.com/jtm/article/14/5/326/1808671 by guest on 27 September 2021 utaneous larva migrans (CLM) is the most fre- Risk factors for developing HrCLM have specifi - Cquent travel-associated skin disease of tropical cally been investigated in one outbreak in Canadian origin. 1,2 This dermatosis fi rst described as CLM by tourists: less frequent use of protective footwear Lee in 1874 was later attributed to the subcutane- while walking on the beach was signifi cantly associ- ous migration of Ancylostoma larvae by White and ated with a higher risk of developing the disease, Dove in 1929. 3,4 Since then, this skin disease has also with a risk ratio of 4. Moreover, affected patients been called creeping eruption, creeping verminous were somewhat younger than unaffected travelers dermatitis, sand worm eruption, or plumber ’ s itch, (36.9 vs 41.2 yr, p = 0.014). There was no correla- which adds to the confusion. It has been suggested tion between the reported amount of time spent on to name this disease hookworm-related cutaneous the beach and the risk of developing CLM. Consid- larva migrans (HrCLM).5 ering animals in the neighborhood, 90% of the Although frequent, this tropical dermatosis is travelers in that study reported seeing cats on the not suffi ciently well known by Western physicians, beach and around the hotel area, and only 1.5% and this can delay diagnosis and effective treatment. -
Comparative Genomics of the Major Parasitic Worms
Comparative genomics of the major parasitic worms International Helminth Genomes Consortium Supplementary Information Introduction ............................................................................................................................... 4 Contributions from Consortium members ..................................................................................... 5 Methods .................................................................................................................................... 6 1 Sample collection and preparation ................................................................................................................. 6 2.1 Data production, Wellcome Trust Sanger Institute (WTSI) ........................................................................ 12 DNA template preparation and sequencing................................................................................................. 12 Genome assembly ........................................................................................................................................ 13 Assembly QC ................................................................................................................................................. 14 Gene prediction ............................................................................................................................................ 15 Contamination screening ............................................................................................................................ -
For Onchocerciasis on Parasitological Indicators of Loa Loa Infection
pathogens Article Collateral Impact of Community-Directed Treatment with Ivermectin (CDTI) for Onchocerciasis on Parasitological Indicators of Loa loa Infection Hugues C. Nana-Djeunga 1,*, Cédric G. Lenou-Nanga 1, Cyrille Donfo-Azafack 1, Linda Djune-Yemeli 1, Floribert Fossuo-Thotchum 1, André Domche 1, Arsel V. Litchou-Tchuinang 1, Jean Bopda 1, Stève Mbickmen-Tchana 1, Thérèse Nkoa 2, Véronique Penlap 3, Francine Ntoumi 4,5 and Joseph Kamgno 1,6,* 1 Centre for Research on Filariasis and Other Tropical Diseases, P.O. Box 5797, Yaoundé, Cameroon; [email protected] (C.G.L.-N.); [email protected] (C.D.-A.); [email protected] (L.D.-Y.); fl[email protected] (F.F.-T.); [email protected] (A.D.); [email protected] (A.V.L.-T.); bopda@crfilmt.org (J.B.); mbickmen@crfilmt.org (S.M.-T.) 2 Ministry of Public Health, Yaoundé, Cameroon; [email protected] 3 Department of Biochemistry, Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon; [email protected] 4 Fondation Congolaise pour la Recherche Médicale (FCRM), Brazzaville CG-BZV, Republic of the Congo; [email protected] 5 Faculty of Science and Technology, Marien Ngouabi University, P.O. Box 69, Brazzaville, Republic of the Congo 6 Department of Public Health, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, P.O. Box 1364, Yaoundé, Cameroon * Correspondence: nanadjeunga@crfilmt.org (H.C.N.-D.); kamgno@crfilmt.org (J.K.); Tel.: +237-699-076-499 (H.C.N.-D.); +237-677-789-736 (J.K.) Received: 24 October 2020; Accepted: 9 December 2020; Published: 12 December 2020 Abstract: Ivermectin (IVM) is a broad spectrum endectocide whose initial indication was onchocerciasis. -
Genomics of Loa Loa, a Wolbachia-Free Filarial Parasite of Humans
ARTICLES OPEN Genomics of Loa loa, a Wolbachia-free filarial parasite of humans Christopher A Desjardins1, Gustavo C Cerqueira1, Jonathan M Goldberg1, Julie C Dunning Hotopp2, Brian J Haas1, Jeremy Zucker1, José M C Ribeiro3, Sakina Saif1, Joshua Z Levin1, Lin Fan1, Qiandong Zeng1, Carsten Russ1, Jennifer R Wortman1, Doran L Fink4,5, Bruce W Birren1 & Thomas B Nutman4 Loa loa, the African eyeworm, is a major filarial pathogen of humans. Unlike most filariae, L. loa does not contain the obligate intracellular Wolbachia endosymbiont. We describe the 91.4-Mb genome of L. loa and that of the related filarial parasite Wuchereria bancrofti and predict 14,907 L. loa genes on the basis of microfilarial RNA sequencing. By comparing these genomes to that of another filarial parasite, Brugia malayi, and to those of several other nematodes, we demonstrate synteny among filariae but not with nonparasitic nematodes. The L. loa genome encodes many immunologically relevant genes, as well as protein kinases targeted by drugs currently approved for use in humans. Despite lacking Wolbachia, L. loa shows no new metabolic synthesis or transport capabilities compared to other filariae. These results suggest that the role of Wolbachia in filarial biology is more subtle All rights reserved. than previously thought and reveal marked differences between parasitic and nonparasitic nematodes. Filarial nematodes dwell within the lymphatics and subcutaneous (but not the worm itself) have shown efficacy in treating humans tissues of up to 170 million people worldwide and are responsible with these infections4,5. Through genomic analysis, Wolbachia have for notable morbidity, disability and socioeconomic loss1. -
Chronic Symptomatic and Microfilaremic Loiasis in a Returned Traveller
CMAJ Practice Clinical images Chronic symptomatic and microfilaremic loiasis in a returned traveller Courtney Thompson BSc MD, Ajith Cy MBBS MD, Andrea K. Boggild MSc MD 24-year-old woman presented for eval- Competing interests: None uation of eosinophilia (4.3 [normal declared. 0.04–0.4] × 109/L), generalized pruritis This article has been peer A reviewed. and recurrent migratory swelling of the wrists. Her symptoms had begun six months after her The authors have obtained return from a three-week stay in rural Camer- patient consent. oon, and had been ongoing for three years. Affiliations:Department of Owing to the epidemiologic and clinical history Medicine (Thompson, Cy, Boggild), University of compatible with loiasis, a blood smear was sub- Toronto; Public Health mitted for microscopic examination, which con- Figure 1: Adult stage of the filarial nematode Loa loa Ontario Laboratories firmed the presence of Loa loa microfilariae migrating in the conjunctiva of the left eye of a (Boggild), Public Health (microfilaremia). 24-year-old woman who had travelled to Cameroon. Ontario; Tropical Disease Unit, Division of Infectious While waiting for treatment with medications Diseases (Boggild), available only through the Special Access Pro- tomatic disease is more common among short- University Health Network- gramme of Health Canada, the patient presented term travellers, the presence of microfilaremia is Toronto General Hospital, to the emergency department with the sensation more consistently seen in patients from endemic Toronto, Ont. of a foreign body in her left eye (Figure 1), and areas who often show no symptoms. Microfilare- Correspondence to: was found to have a nemotode migrating in the mia is not commonly seen in expatriates or trav- Andrea Boggild, andrea [email protected] conjunctiva. -
Public Health Service Centers for Disease Control and Prevention (CDC) Memorandum Date: January 7, 2011 From: WHO Collaborat
Public Health Service Centers for Disease Control DEPARTMENT OF HEALTH & HUMAN SERVICES and Prevention (CDC) Memorandum Date: January 7, 2011 From: WHO Collaborating Center for Research, Training and Eradication of Dracunculiasis Subject: GUINEA WORM WRAP-UP #202 To: Addressees “Perseverance and spirit have done wonders in all ages.” George Washington GHANA IS DONE Sometimes the sight and sound of bat against ball or gloved fist against an opponent’s head lets seasoned observers sense a homerun or knockout has occurred even before the ball leaves the park or the boxer hits the floor. We feel that way now about Guinea worm eradication in Ghana. With seven consecutive months of zero cases reported since May 2010 and fourteen months after reporting its last known uncontained case in October 2009, Ghana has finally conquered Guinea worm disease. (Figure 1) This early conclusion is unprecedented. Up to now the editors of Guinea Worm Wrap-Up have, with good reason, warned Ghana repeatedly about the perils of over-confidence or premature declarations of success. We have never before felt as assured about a national milestone of elimination before at least twelve consecutive months of indigenous cases have passed as we do now. And that this should occur in Ghana is especially wondrous, given that country’s exceptionally tortuous and delayed arrival at this point in its campaign. The long hoped-for portents were there with the record-breaking 85% reduction in cases between 2007 (3,358 cases) and 2008 (501 cases), the 97% reduction in cases between 2009 (242 cases) and 2010 (8 cases), and the obsessive attention to detecting every case, containing every worm, and tracing every source that Ghana’s Guinea Worm Eradication Program has manifest recently. -
Loaina Gen. N. (Filarioidea: Onchocercidae) for the Filariae Parasitic in Rabbits in North America
Proc. Helminthol. Soc. Wash. 51(1), 1984, pp. 49-53 Loaina gen. n. (Filarioidea: Onchocercidae) for the Filariae Parasitic in Rabbits in North America MARK L. EBERHARD AND THOMAS C. ORIHEL Department of Parasitology, Delta Regional Primate Research Center, Covington, Louisiana 70433 ABSTRACT: A new genus, Loaina, is erected to accommodate the species of Dirofilaria parasitic in rabbits in North America. The genus is comprised of two species, Loaina scapiceps (Leidy, 1886) comb. n. and Loaina uniformis (Price, 1957) comb, n.; L. uniformis is designated as the type species. The genus Loaina is distinguished morphologically from Dirofilaria and other Dirofilariinae by a combination of characters, including an extremely short tail in both sexes, an undivided esophagus, a post-esophageal vulva, short, simple spicules, a small number of caudal papillae grouped at the posterior extremity of the body in the male, and a sheathed microfilaria. Two other species, D. timidi and D. roemeri are not regarded to be valid species of Dirofilaria. The genus Dirofilaria should be restricted strictly to those species having unsheathed microfilariae. Morphologically, the genus Loaina most closely resembles the genus Loa. The two genera are distinct, however, on the basis of host preference, size and cuticular ornamentation. A review of the morphological features of the ments of anatomical features are from stained speci- dirofilarias that parasitize Louisiana mammals mens. revealed that there were marked morphological Description differences between those species of Dirofilaria Railliet and Henry, 1910 infecting rabbits in Loaina gen. n. North America, i.e., D. uniformis Price, 1957 Dirofilaria Railliet and Henry, and D. scapiceps (Leidy, 1886), and other mem- 1910, in part bers of the genus. -
Albenza (Albendazole)
Market Applicability Market DC FL FL FL GA KS KY MD NJ NV NY TN TX WA & MMA LTC FHK Applicable X X NA NA X NA X X X X X NA NA X *FHK- Florida Healthy Kids Albenza (albendazole) Override(s) Approval Duration Prior Authorization 1 year Quantity Limit Medications Quantity Limit Albenza (albendazole) May be subject to quantity limit APPROVAL CRITERIA Requests for Albenza (albendazole) may be approved if the following criteria are met: I. Individual is using for the treatment of one of the following: A. Neurocysticercosis caused by Taenia solium (pork tapeworm); OR B. Hydatid disease caused by Echinococcus granulosus (dog tapeworm); OR C. Ascariasis caused by Ascaris lumbricoides (roundworm) (DrugPoints B IIa, AHFS); OR D. Microsporidiosis (DrugPoints B IIa, AHFS); OR E. Trichuriasis caused by Trichuris trichiura (whipworm) (DrugPoints B IIa, AHFS); OR F. Baylisascariasis caused by Baylisascaris procyonis (raccoon roundworm) (AHFS); OR G. Loiasis caused by Loa loa (AFHS); OR H. Cutaneous larva migrans caused by dog and cat hookworms (AFHS); OR I. Intestinal hookworm infection caused by Ancylostoma duodenale, Ancylostoma caninum or Necator americanus (AHFS); OR J. Toxocariasis caused by Toxocara canis or Toxocara cati (dog and cat roundworm) (AHFS); OR K. Strongyloidiasis caused by Strongyloides stercoralis (threadworm) (AFHS); OR L. Trichinellosis caused by Trichinella spiralis (AHFS); OR M. Capillariasis caused by Capillaria philippinensis (AHFS); OR N. Gnathostomiasis caused by Gnathostoma spinigerum (AHFS); OR O. Clonorchis sinensis (Chinese liver fluke) (AFHS); OR P. Opisthorchis (liver fluke) (CDC-Opisthorcis); PAGE 1 of 2 08/29/2018 New Program Date 08/29/2018 This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. -
Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria
JMIR RESEARCH PROTOCOLS Smit et al Protocol Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya Menno R Smit1, MD, MPH; Eric Ochomo2, PhD; Ghaith Aljayyoussi1, PhD; Titus Kwambai2,3, MSc, MD; Bernard Abong©o2, MSc; Nabie Bayoh4, PhD; John Gimnig4, PhD; Aaron Samuels4, MHS, MD; Meghna Desai4, MPH, PhD; Penelope A Phillips-Howard1, PhD; Simon Kariuki2, PhD; Duolao Wang1, PhD; Steve Ward1, PhD; Feiko O ter Kuile1, MD, PhD 1Liverpool School of Tropical Medicine (LSTM), Liverpool, United Kingdom 2Centre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya 3Kisumu County, Kenya Ministry of Health (MoH), Kisumu, Kenya 4Division of Parasitic Diseases and Malaria, Center for Global Health, U.S. Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States Corresponding Author: Menno R Smit, MD, MPH Liverpool School of Tropical Medicine (LSTM) Pembroke Place Liverpool, L3 5QA United Kingdom Phone: 254 703991513 Fax: 44 1517053329 Email: [email protected] Abstract Background: Innovative approaches are needed to complement existing tools for malaria elimination. Ivermectin is a broad spectrum antiparasitic endectocide clinically used for onchocerciasis and lymphatic filariasis control at single doses of 150 to 200 mcg/kg. It also shortens the lifespan of mosquitoes that feed on individuals recently treated with ivermectin. However, the effect after a 150 to 200 mcg/kg oral dose is short-lived (6 to 11 days). Modeling suggests higher doses, which prolong the mosquitocidal effects, are needed to make a significant contribution to malaria elimination.